Received May 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 9L944 | — |
had received only the adjuvant portion of Shingrix; received only the adjuvant portion; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate preparation of medication in a patient who received Herpes zoster (Shingrix) (batch number 9L944, expiry date 30-MAR-2027) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced inappropriate preparation of medication (Verbatim: had received only the adjuvant portion of Shingrix) and inappropriate dose of vaccine administered (Verbatim: received only the adjuvant portion). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK receipt date: 09-MAY-2025 Other HCP reported that there were 5 patients involved in an incident where they didn't know which of them had received only the adjuvant portion of Shingrix. Also, reporter mentioned that they were investigating this incident, but that it may be possible that they readministered the doses to the patients, leading to a potential 3rd dose administered to any of these patients, as some of them had already received the 1st dose of Shingrix. The patient received only adjuvant of Shingrix, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered.; Sender's Comments: US-GSK-US2025057630:SAME REPORTER US-GSK-US2025057623:same reporter